Background: Graft survival depends on adequate immunosuppression. To evaluate the effect on the immune system of immunosuppressive therapies using calcineurin inhibitors (CNIs), several pharmacodynamic indices have been proposed to complement pharmacokinetic data. In this preliminary study we compared some of these parameters during combined immunosuppressant therapies. Methods: We treated 65 stable renal transplant recipients with cyclosporin A (CsA; n ‫؍‬ 16), tacrolimus (TRL; n ‫؍‬ 10); CsA ؉ mycophenolate mofetil (MMF; n ‫؍‬ 14); TRL ؉ MMF (n ‫؍‬ 13), and MMF (n ‫؍‬ 12). Twelve nontreated healthy controls were also included. Calcineurin activity (CNA) in peripheral blood mononuclear cells was measured using 32 P-labeled peptide. Interleukin-2 (IL-2) and interferon-␥ production in phytohemagglutinin-activated whole blood were measured at 0 and 2 h postdose. The areas under the curves, c min , c max , and concentration at 2 h (c 2 h ) were also measured. 
Current standard immunosuppressive therapy protocols are generally highly effective in preventing acute rejection. However, long-term immunosuppressive treatment has substantial adverse effects, and its efficacy in preventing chronic rejection is poor. For this reason there is growing interest in evaluating the efficacy and safety of lower toxicity immunosuppressive therapies such as combinations of calcineurin inhibitors (CNIs) 4 at low doses and antimetabolites such as mycophenolate mofetil (MMF).
The measurement of blood concentrations of immunosuppressants provides only an indirect evaluation of the degree of immunosuppression attained in an individual patient (1, 2 ) When combined treatments are used, the biological impact may be higher than that predicted by the individual blood concentrations of each immunosup-pressant. Thus the measurement of several markers has been proposed to assess the impact of immunosuppressants on the immune systems of individual patients. Various approaches have been proposed for the pharmacodynamic (PD) monitoring of immunosuppressants: One is evaluation of the activity of the specific target enzyme, such as calcineurin activity (CNA) for cyclosporin A (CsA) and tacrolimus (TRL) (3) (4) (5) , inosine monophosphate dehydrogenase for MMF (6 -8 ) , and P70S6 kinase activity for sirolimus (1, 9 ) . A second approach is the evaluation of an intermediate step in the action mechanism: for example, the measurement of interleukin-2 (IL-2) and interferon-␥ (IFN-␥) production in vitro in whole blood for CsA and TRL (10 ) , and DNA duplication for MMF and sirolimus (7, 11 ) . A third possibility is the measurement of collateral markers modified by the presence of the immunosuppressant, such as the T-lymphocyte surface antigens CD25, CD71, and CD154 (12, 13 ) .
CsA and TRL are widely used to prevent rejection in allotransplantation. Both drugs have the same target: the serine/threonine phosphatase calcineurin (CN), or PP2B. One important substrate of this phosphatase is the nuclear factor of activated T cells. Nuclear factor of activated T cells remains in the cytoplasm when it is inactive. It is activated by dephosphorylation effected by CN and migrates to the nucleus, where it participates in the induction of the transcription of genes necessary for lymphocyte expansion, such as IL-2, IFN-␥, IL-4, IL-3, and tumor necrosis factor-␣ (14 ) . To inhibit CNA, CsA and TRL must bind to the immunophilins present in the cytoplasm of T lymphocytes: cyclophilins in the case of CsA and FKbinding proteins (FKBPs) in the case of TRL. CsA-cyclophilin (CsA-cyclophilin A) and TRL-FKBP (TRL-FKBP12) complexes inhibit ϳ80 -90% of CNA (15) (16) (17) .
To our knowledge, no data on the correlation between CNA and IL-2 or IFN-␥ production have been reported in stable renal patients receiving CsA or TRL alone or in combined therapy with MMF.
The aims of this study were (a) to determine the correlation between the pharmacokinetic (PK) parameters [c min , c max , c 2 h , and area under the curve (AUC)] for CsA and TRL and the different PD indices proposed (CNA and IL-2 and IFN-␥ production), and (b) to assess the importance of combined therapies on the measurement of CNA and IL-2 and IFN-␥ production. Establishing additional PD indices to measure the biological impact of immunosuppressants can be of help in the introduction of new immunosuppressant combinations, in the introduction of lower-than-standard doses, and in the study of individual variability in certain special cases.
Patients and Methods patients
This was a nonrandomized (non-placebo-controlled) trial. The study was approved by the Institutional Ethical Review Board of Hospital Clínic of Barcelona, and informed consent was obtained from all participants. Sixtyfive stable renal transplant patients (39 males) were included in the study. The mean (SD) age was 58 (14) years, with a mean time since renal transplantation of 56 (14) months. Patients were divided into five groups according to their maintenance immunosuppression treatment: CsA monotherapy (n ϭ 16), TRL monotherapy (n ϭ 10), CsAϩMMF (n ϭ 14), TRLϩMMF (n ϭ 13), and MMF monotherapy (n ϭ 12). The immunosuppressive drug treatment also included corticoids. All patients were stable, with acceptable renal function [mean serum creatinine 16.0 (4.5) mg/L], and with no episodes of acute rejection in the previous 6 months. No 
cell preparation
Human peripheral blood mononuclear cells (PBMCs) were obtained from the mononuclear cell layer of the Ficoll-Hypaque gradient. The remaining red blood cells were lysed during a short incubation period (10 s) in water followed by addition of an equal volume of phosphate-buffered saline (2ϫ concentrate). Washed and pelleted PBMCs (6 ϫ 10 6 ) were lysed with 0. The phosphorylated peptide was purified by Sep-Pak C 18 chromatography. Columns were prepared using syringes to apply 3 mL of 300 mL/L acetonitrile in 1 g/L TFA followed by 5 mL of 1.0 g/L TFA. The contents of the kinase reaction were then slowly applied to the column. The column was washed with 400 mL of TFA to remove unincorporated ATP. The peptide was then eluted by addition of five 0.5-mL volumes of 300 mL/L acetonitrile in 1.0 g/L TFA. The radiolabeled peptide fractions were pooled and evaporated under argon gas, resuspended with 2 mL of buffer 1 [20 mmol/L Tris-HCl (pH 8), 100 mmol/L NaCl, 6 mmol/L MgCl 2 , 0.10 mmol/L CaCl 2 , 0.50 mmol/L DTT, and 0.10 g/L bovine serum albumin], and stored at Ϫ20°C (18 ) .
The interassay CV for peptide labeling was 23% and was assessed by phosphorylating the synthetic peptide on different days with the same batch of [␥-32 P]ATP and protein kinase. The intraassay CV of the phosphorylation assay was 5.6% and was assessed by performing five replicates of the phosphorylation assay on the same day.
phosphatase assay (cna measurement) CNA was measured in treated patients and in the NHC group in the morning predose and 2 h postdose.
Hypotonic lysates of PBMCs were evaluated for their ability to dephosphorylate a 32 P-serine-labeled 19-aminoacid peptide substrate (19mer) in the presence of okadaic acid, a phosphatase type 1 and 2A inhibitor, as described previously by Fruman et al. (18 ) . Background phosphatase 2C activity (CsA-and okadaic acid-resistant activity) was determined and subtracted from each sample, with the assay performed in the presence and absence of excess added CsA or TRL. The remaining phosphatase activity was taken as CNA (PP2B).
Assays were performed in a final volume of 60 L, in four different tubes. In all tubes we added 20 L of PBMC lysates and 20 L of 32 P-labeled phosphopeptide (final concentration, 5 mol/L) as substrate. In addition, in tube 1 we added 20 L of buffer 1, in tube 2 we added 20 L of buffer 2 (buffer 1 containing 500 nmol/L okadaic acid), in tube 3 we added 20 L of buffer 3 (buffer 2 containing 10 mol/L CsA), and in tube 4 we added 20 L of buffer 4 (buffer 2 containing 100 g/L TRL). Buffer 4 has not been described before and was added to better evaluate samples from patients treated with TRL. We found no significant differences between buffers 3 and 4. The results were expressed in relationship to classic buffer 3. In addition, we measured the total activity of the substrate by counting 20 L in a Beckman scintillation counter on the day of the assay, by measuring the spontaneous release via incubation of the substrate without lysate, and the capacity of AP (20 U) to dephosphorylate the substrate (maximum dephosphorylation).
The mixture was incubated for 30 min at 30°C, and the reaction was stopped by the addition of 0.8 mL of 100 mmol/L K 2 HPO 4 containing 50 g/L trichloroacetic acid. We then added 200 L of cation-exchange resin (AG50W-X8, 100 -200 mesh) and shook the suspension for 30 min at room temperature.
Cation-exchange resin was prepared in a batch procedure as follows. We suspended 2 g of dry resin was in 50 mL of water. After settling, the water was decanted and replaced with 5 mL of 1 mol/L NaOH. After mixing and settling, the supernatant was decanted completely and replaced with 10 mL of 1 mol/L HCl. After mixing and settling, the supernatant was again decanted, and the resin was washed with 20 mL of water. After removal of this supernatant, the resin was suspended in 2.2 mL of water and stored at 4°C.
After the incubation, we centrifuged for 2 min at 12 000g. The released inorganic phosphate contained in the supernatant (500 L) was measured by scintillation counting (18 ) .
The initial results indicated the need to introduce an internal value to minimize the variability among different batches of 32 P-labeled peptide and the radioactive decay. The internal value was defined as the capacity of AP to dephosphorylate the synthetic peptide, and it was considered to be the maximum dephosphorylation that could be observed with the peptide batch in use. The internal value was introduced in all remaining experiments. The results for CNA were expressed as: percentage of AP ϭ 100 (cpm released by the sample)/cpm released by the AP). CsAresistant phosphatase values (standard method) or TRLresistant phosphatase values (buffer 4) were subtracted Clinical Chemistry 49, No. 11, 2003 from the phosphatase activity in presence of okadaic acid and CNA (PP2B) was expressed as percentage of AP.
The interassay and intraassay CVs for measurement of CNA were 8% and 5%, respectively. CNA was assessed by individuals who were blinded to the treatment allocation of the patient. measurement of il-2 and ifn-␥ production IL-2 and IFN-␥ production was measured in treated patients and in the NHC group in the morning predose and 2 h postdose. IL-2 and IFN-␥ production was assessed by individuals who were blinded to the treatment allocation of the patient.
We measured the IL-2 and IFN-␥ production in 950 L of whole blood incubated with 50 L of PHA (1 g/L) and shaken for 5 h at 37°C. At the end of the incubation, the samples were centrifuged in an Eppendorf microcentrifuge for 2 min, and the supernatant was removed and stored at Ϫ80°C until assayed. IL-2 and IFN-␥ concentrations were measured by ELISA. The detection limits were 3 ng/L for IL-2 and 80 IU/L for IFN-␥ (10 ).
measurement of blood concentrations of CsA and trl
CsA concentrations in whole blood were determined by Emit, ® with a specific monoclonal antibody, on a Cobas Mira automated analyzer (Dade-Behring) as described previously (19 ) . TRL monitoring was carried out by MEIA assay with an IMx analyzer (Abbott) (20 ) . Blood samples for determining the CsA and TRL blood concentrationtime curve AUCs were drawn predose (c min ) and at 1, 2, 4, 6, 8, 10, and 12 h after the morning dose from stable, treated renal patients. AUCs were calculated by the linear trapezoidal rule.
measurement of plasma concentrations of mycophenolic acid
Plasma concentrations of mycophenolic acid (MPA) were analyzed by a validated HPLC-ultraviolet detection method described elsewhere (21, 22 ) . The total run time was 12 min. The working range for MPA was 0.10 -50 mg/L, and the within-and between-run CVs ranged from 4.5% to 9.7%.
International CsA, TRL, and MPA Testing Scheme Samples were also analyzed as external controls (from D.W. Holt, European Quality Control, London, UK).
statistics
Unless specified, all results are expressed as the median and the 25th-75th percentiles or the confidence interval. In some graphs, the 25th and 75th percentiles are shown. Statistical differences between groups were assessed using the nonparametric Mann-Whitney test. Differences are indicated on the graphs with an asterisk. Correlations between variables were assessed by another nonparametric test, the Spearman test (), with SPSS statistical software (SPSS Inc.). P Ͻ0.05 was considered significant.
Results

pk profiles of the treated patients
The PK parameters studied were c min , c 2 h , c max , and AUC. The results were as expected according to doses received. Note that MMF doses in the TRLϩMMF group were lower than for the other groups; as a consequence, the PK parameters are also reduced (Table 1) .
cna measurements in vitro
Measurement of CNA was validated in vitro. PBMCs from healthy donors were cultured in the presence of 
cna measurements in patients
CNA was evaluated at 0 and 2 h postdose in the PBMCs of stable renal transplanted patients treated with CsA, TRL, MMF, CsAϩMMF, and TRLϩMMF (Fig. 2) .
The median (25th-75th percentiles) CNA was 37.45 (21.32-56.15)% AP in the NHC group and 24.20 (17.72-35.58)% AP in the MMF group. These values were significantly lower in the CsA group than in NHC or MMF group, both predose [0 h; 6.42 (5.47-10.01)% AP] and 2 h postdose [3.87 (3.00 -6.85)% AP; P Ͻ0.01; Fig. 2A (Fig. 2) .
il-2 and ifn-␥ production in whole blood from patients IL-2 and IFN-␥ production after in vitro stimulation of whole blood with PHA was evaluated in the study groups (Figs. 3 and 4) . Results showed considerable variability in IL-2 production in the NHC and MMF groups. IL-2 production was lower 2 h postdose in all groups other than the NHC group (Fig. 3) We observed no predose differences in IFN-␥ production between the control group and patients treated only with CNIs [median (25th-75th percentiles), 22.39 (9.78 -34.34) IU/mL vs 29.25 (25.55-31.90) IU/mL]. Postdose, blood from the CsA, TRL, and TRLϩMMF groups showed clear inhibition compared with blood from the NHC group (Fig. 4) .
pd and pk correlations
The correlation between the classic PK parameters and PD indices was studied with the nonparametric Spearman test (). P Ͻ0.05 was considered significant (Table 2) .
There was a significant inverse correlation (r Ͼ0.7) between CNA 2 h postdose and the AUC for all groups studied and for CNA 2 h postdose and c 2 h , especially in the CsA and CsAϩMMF groups.
IL-2 production 2 h postdose and c 2 h also were significantly inversely correlated in the CsA, CsAϩMMF, and TRLϩMMF groups, as were IL-2 production 2 h postdose and AUC in the TRLϩMMF group.
There was no correlation between IFN-␥ and c min in any group. In contrast, IFN-␥ production was signifi- Table 2) . To identify the redundancy among PD indicators, we studied the correlations between the pharmacodynamics at different times and the various PD indicators (Table 3) . We found a strong correlation between CNA 0 h predose and CNA 2 h postdose in all groups (r ϭ 0.93-0.96). We also found a significant correlation between IL-2 production 0 h predose and IL-2 production 2 h postdose in the CsA groups (r ϭ 0.92-0.96) and the TRL groups (r ϭ 0.75-0.82; Table 3 ).
Discussion
This study was designed to evaluate the potential usefulness of different PD assays, initially described for the evaluation of CsA treatment, in the evaluation of TRL treatment and of combined therapies with MMF.
This study included PD markers such as CNA in PBMCs and IL-2 and IFN-␥ production in whole blood along with classic PK parameters, and compared them in stable renal transplant patients treated with CsA or TRL alone or in combination with MMF.
We decided to measure CNA in PBMCs and not in whole blood, as other authors have done (23 ), for several reasons: Our main interest was the impact of the drug on enzyme activity inside the lymphocytes, which are the main producers of relevant interleukins involved in the alloresponse. This impact probably depends on the equilibrium between uptake, cyclophilin binding, P-glycoprotein-dependent excretion, and probably other factors re- ;, predose; Ⅺ, 2 h postdose. ‫,ء‬ P Ͻ0.05 compared with the NHC group. lated to each cell type. In our opinion the use of whole blood to measure CNA has two drawbacks: (a) the CN of lymphocytes represents only a small part (Ͻ10%) of the whole-blood CN (23 ) , and thus the greater part of the CNA measured when whole blood is used is not relevant; and (b) more importantly, the technique involves a cell disruption step in which the CsA or TRL stored in red blood cells becomes available for lymphocyte CN. In vivo, only intralymphocytic CNIs are available for lymphocyte CN; therefore, the measurement of CNA in whole blood does not reflect the real impact of inhibitors on the immune system. However, to evaluate IL-2 and IFN-␥ production, we decided to use whole blood because with the technique described by Stein et al. (10 ) the lymphocyte microenvironment was maintained throughout the assay time (5 h at 37°C), and intracellular concentrations changes in CNIs were avoided.
The profile chosen to evaluate PD indices was predose and 2 h postdose for all groups. Although the CsA peak is reached 1 h after drug administration, it is generally agreed that CsA concentrations at 2 h (c 2 h ) correlate better with AUC, c max , and clinical impact. In fact, c 2 h values are currently used to adjust CsA concentrations in clinical practice (24, 25 ) . In addition, Caruso et al. (23 ) showed that the nadir of CNA in PBMCs was at 3 h postdose and that CNA values were very similar at 1, 2, 3, and 5 h postdose. Those authors noted that there was a delay between c max and the nadir of CNA in PBMCs.
Our results confirm previous reports (4, 5 ) that measurement of CNA in the PBMCs of patients treated with CsA is feasible with the technique described by Fruman et al. (18 ) . Our findings are similar to those reported by Batiuk et al. (5 ) , Kung et al. (26 ) , and Halloran et al. (27 ) , who did not observe complete inhibition of CNA in vivo in CsA-and TRL-treated groups.
The inhibition of CNA observed in the CsA and TRL groups compared with the NHC group (83% and 77%, respectively, at 0 h; 90% and 85% at 2 h postdose) was higher than in previous reports. This is probably attributable to our decision to express the CNA results as percentages of the capacity of an AP to release 32 P from the synthetic peptide, which in our opinion increases the stability of this marker by minimizing the variability attributable to differences in the batches of 32 P-labeled peptides and radioactivity decay between assays.
The variability of CNA in TRL-treated patients was higher than in those receiving CsA. Some authors attribute this variability to the fact that the CsA-cyclophilin complex has better accessibility to the active site of the synthetic peptide used (27 ) . Others account for these differences by pointing to the existence of a limiting factor, the active immunophilins present in the lymphocytes; it appears that active FKBPs have a greater limiting effect than active cyclophilins (26 ) . In addition, by working with disrupted cells we introduced conditions that are different from those in intact cells, above all in the distribution of certain immunophilins in the various compartments in the lymphocyte. In other words, we may have altered the probability of the formation of the immunosuppressant-immunophilin active complex (CsA-cyclophilin and TRL-FKBP). However, when we used a buffer with TRL in the phosphatase assay (buffer 4; described in Materials and Methods) there was no significant change in the results.
In combined therapies with CNIs and MMF, the CNA measurement does not directly reflect the additional immunosuppressive effect of MMF. The measurement of IL-2 production, in contrast, seems to reflect the effect provided by the presence of MMF in CNI therapies, especially postdose. In the NHC group, IL-2 production was highly variable. Variability in the CNI-treated groups was lower, especially postdose. Because of the short in vitro culture time used, IL-2 production depended on the number of preactivated cells present in vivo in each individual. The decrease in variability in the CNI-treated patients postdose indicates that the variability in the number of preactivated cells present in the patients does not disqualify IL-2 production as an indicator of the CNI effect. However, it is likely that longer in vitro incubation times could reduce this variability.
The CNA in patients receiving monotherapy with MMF was not statistically different from that in the NHC control, but it was higher than in patients treated with CNIs.
The decrease in IL-2 production in patients receiving MMF in addition to CNIs in comparison with those receiving CNI alone was probably attributable to the inhibitory effect of MMF on clonal expansion of activated lymphocytes. The decrease in the number of active lym- phocytes, rather than a direct effect of MMF on CNA or in the production of IL-2 and IFN-␥, was probably responsible for the decrease in production. IFN-␥ production is highly variable in this population. There was a lack of correlation between c min and IFN-␥ at 0 h, indicating that IFN-␥ is not a useful marker for these studies.
IL-2 production was lower in the CsAϩMMF group than in the CsA-alone group at 2 h. These differences can not be explained by differences in the CsA concentrations: there was no significant differences in CsA dose [ ] ; therefore, the presence of MMF seems to be responsible for the additional inhibitory effect on IL-2 production seen at 2 h in the CsAϩMMF group.
IL-2 production was lower in the TRLϩMMF group than in the TRL-alone group at 2 h. Those differences cannot be explained by differences in the TRL concentrations: neither the doses nor c min showed significant differences. The c 2 h was even lower in the TRLϩMMF group than in the TRL-alone group [median (25th-75th percentiles), 13.50 (11.70 -17.10) and 21.90 (10.35-33.15) g/L, respectively]; therefore, the presence of MMF seems to be responsible for the additional inhibitory effect on IL-2 production seen at 2 h in the TRLϩMMF group as well.
These two results suggest that the addition of MMF to CNI therapies increases the inhibition of IL-2 production, although it does not directly affect CNA. The reason could be that reducing the clonal expansion of activated T cells reduces the number of cells ready to produce IL-2 in our in vitro assay.
Several strategies have been proposed in the past to monitor the pharmacodynamics of CNI immunosuppressants. Here we compared some of them in monotherapy and combined therapies to identify the most useful ones to monitor the biological impact of new combinations of immunosuppressants, different doses from those considered standard, or the study of problematic patients.
In our study, the PD indicator with the best correlation with AUC and c 2 h was CNA, followed by IL-2 production. In general, IFN-␥ had the poorest correlation with PK parameters; the correlation was particularly poor between IFN-␥ 0 h and c min . IL-2 production, however, seems to reflect the additional immunosuppressive effect introduced by MMF in combined therapies. This additional effect was not detected by CNA determination.
There was a very good correlation with CNA at 0 and 2 h for both CsA and TRL and with IL-2 at 0 and 2 h, especially for CsA.
In conclusion, the measurement of CNA may be a good predictor of the immunosuppression caused by CsA or TRL monotherapies, whereas IL-2 production is potentially more useful for monitoring combined therapies comprising CNIs and MMF.
